← Search & browse all drugs
SENSORY ORGANS › OPHTHALMOLOGICALS › MYDRIATICS AND CYCLOPLEGICS › Sympathomimetics excl. antiglaucoma preparations
phenylephrine
S01FB01
Forms & Strengths
- Ophthalmic Solution: 2.5%, 10%
Adult Dosing
- Vasoconstriction/Mydriasis: 1 drop of 2.5% or 10% solution into the conjunctival sac as clinically indicated.
- Uveitis (Posterior Synechiae prophylaxis): 1 drop of 2.5% or 10% solution.
- Ophthalmoscopy: 1 drop of 2.5% solution 15 to 30 minutes prior to examination.
Pediatric Dosing
- Mydriasis in infants >1 year: 2.5% ophthalmic solution (use 10% strictly contraindicated in neonates and infants due to risk of systemic toxicity).
Indications
- Production of mydriasis for ophthalmic examination or surgical procedures.
- Vasoconstriction of conjunctival vessels.
- Prophylaxis and treatment of posterior synechiae in uveitis.
Mechanism of Action
- Direct-acting alpha-1 adrenergic receptor agonist. Causes contraction of the dilator pupillae muscle (resulting in mydriasis) and constriction of arterioles in the conjunctiva.
Contraindications
- Hypersensitivity to phenylephrine or any component of the formulation.
- Angle-closure glaucoma (or narrow angles at risk of precipitation).
- Use of 10% solution in neonates, infants, and patients with severe cardiovascular disease, aneurysm, or uncontrolled hypertension.
Adverse Reactions
- Transient stinging and burning upon instillation.
- Blurred vision and photophobia.
- Increased intraocular pressure.
- Systemic effects (rare with ophthalmic use, but possible via nasolacrimal absorption): hypertension, tachycardia, arrhythmia, subarachnoid hemorrhage, myocardial infarction.
Drug Interactions
- Monoamine Oxidase Inhibitors (MAOIs): May precipitate severe hypertensive crisis due to enhanced pressor response.
- Tricyclic Antidepressants (TCAs) and sympathomimetics: Potentiate pressor and mydriatic effects.
- Beta-blockers (systemic): May interact to cause acute blood pressure changes.
Curated Content: Needs Vetting Before Put to Clinical Use